Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global balloon for peripheral arterial disease market was valued at USD 2.02 billion in 2024 and is projected to reach USD 4.25 billion by 2031, exhibiting a CAGR of 11.5% during the forecast period.
Balloon catheters for peripheral arterial disease (PAD) are specialized medical devices used to open blocked arteries in the legs, kidneys, and other peripheral arteries. These devices enable minimally invasive procedures such as angioplasty and atherectomy by providing controlled inflation to compress plaques and restore blood flow. Key product categories include ordinary balloons, drug-eluting balloons (DEB), and specialized balloons with specific coatings or structural features.
Market growth is primarily driven by the increasing prevalence of peripheral artery disease globally, particularly among aging populations with higher risk factors like diabetes and hypertension. According to the American Heart Association, over 200 million people globally were affected by PAD in 2024, with projections indicating continued growth due to demographic shifts and lifestyle factors. The market also benefits from technological advancements in drug delivery systems and the growing preference for minimally invasive procedures over traditional surgery.
Recent regulatory approvals have accelerated market expansion. In 2024, the U.S. FDA cleared several next-generation balloon catheters with enhanced drug delivery capabilities, including products from Boston Scientific and Medtronic. Similarly, European regulators have approved next-generation devices with improved safety profiles. These regulatory milestones facilitate market access and adoption across key markets.
Key market players include BD, Boston Scientific, Abbott Laboratories, Cordis, Acotec, Biotronik, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd., Cook Medical, Lepu Medical, Zylox-Tonbridge Medical Technology Co., Ltd., and LeoMed. These companies compete through product innovation, strategic partnerships, and geographic expansion, particularly in high-growth markets across Asia and Latin America.
Rising Prevalence of Peripheral Arterial Disease
The increasing global prevalence of peripheral arterial disease (PAD), particularly among aging populations and those with diabetes, is creating sustained demand for interventional treatments. With over 200 million people affected worldwide, the patient pool continues to grow annually.
Advancements in Balloon Technology
Recent innovations in drug-coated balloons (DCBs) and specialized balloon materials have significantly improved treatment outcomes. Technologies like paclitaxel-coated balloons have demonstrated up to 70% reduction in restenosis rates compared to conventional angioplasty.
Drug-coated balloons represent a paradigm shift in peripheral artery treatment, offering targeted therapy with reduced systemic side effects compared to oral medications
Growing physician preference for minimally invasive procedures over traditional surgical options continues to drive adoption, with over 1.5 million peripheral interventions performed annually worldwide.
MARKET CHALLENGES
High Cost of Advanced Balloon Systems
Premium pricing of drug-coated and specialty balloons creates adoption barriers in cost-sensitive markets. Single-use advanced balloons can cost between $1,200 and $2,500, creating budget constraints for healthcare systems with limited interventional radiology budgets.
Other Challenges
Regulatory Hurdles
Stringent regulatory requirements for combination products (device + drug) delay market entry and increase development costs. The average FDA approval process for a new drug-coated balloon takes 18-24 months with costs exceeding $2 million in clinical trial requirements alone.
Limited Reimbursement
In some regions, reimbursement rates fail to keep pace with technology advancements. Medicare and private insurers often provide limited coverage for certain balloon procedures, particularly for complex cases requiring multiple or specialized balloons.
Economic Constraints on Healthcare Systems
Post-pandemic healthcare budget constraints have forced many institutions to prioritize essential services over elective procedures. Hospital budget cuts have particularly affected capital-intensive departments like interventional radiology, where balloon angioplasty equipment represents a significant investment.
Emerging Markets Expansion
Developing economies present massive growth opportunities as healthcare infrastructure improves. Countries like India, Brazil, and Indonesia are experiencing double-digit growth in interventional cardiology and radiology procedures. The Asia-Pacific market is projected to grow at 15.3% CAGR through 2028, the fastest globally.
Technology Convergence
Integration of artificial intelligence in procedural planning and real-time imaging guidance creates new opportunities for precision balloon applications. AI-assisted angioplasty procedures are showing 30% improvement in optimal balloon placement and inflation parameters.
Outpatient Adoption Growth
Shifting procedures from hospital settings to ambulatory surgical centers creates new market segments. Outpatient peripheral interventions have grown 28% year-over-year, creating demand for specialized balloon systems designed for outpatient settings with simplified logistics and reduced procedure times.
| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Drug-Eluting Balloons dominate the market due to their superior efficacy in preventing restenosis and providing better long-term patency rates compared to conventional balloons, as they release anti-proliferative drugs directly at the lesion site. |
| By Application |
|
Femoropopliteal Artery Disease represents the largest application segment due to the high prevalence of atherosclerosis in lower extremities and the critical need for revascularization procedures in this anatomical region to prevent limb loss. |
| By End User |
|
Hospitals and Medical Centers remain the dominant end-user segment due to their comprehensive vascular surgery departments, advanced interventional radiology facilities, and high patient volumes requiring peripheral arterial disease interventions with specialized balloon technologies. |
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
Medtronic plc (Ireland) maintains its leadership position through its extensive portfolio of peripheral balloon catheters and strong R&D investments, while Boston Scientific Corporation (USA) follows closely with its specialized balloon technologies for below-the-knee interventions and chronic total occlusions.
Abbott Laboratories (USA) has gained significant market share through its acquisition strategies and focus on drug-coated balloons, while Becton, Dickinson and Company (USA) leverages its extensive distribution network to expand its interventional portfolio. Cook Medical (USA) continues to innovate with specialized balloons for complex lesions, and Terumo Corporation (Japan) expands its Asia-Pacific presence with advanced balloon technologies.
Recent years have seen increased M&A activity, with major players acquiring specialized balloon technology startups to enhance their product portfolios. Expansion into emerging markets, particularly in Asia and Latin America, has become a key growth strategy for leading players.
Partnerships with research institutions and academic medical centers are accelerating innovation in balloon coating technologies and drug-elution technologies. Several companies are also investing in training programs to increase physician adoption of advanced balloon technologies.
List of Key Peripheral Arterial Disease Balloon Companies ProfiledMedtronic plc (Ireland)
Abbott Laboratories (USA)
Becton, Dickinson and Company (USA)
Cook Medical (USA)
Terumo Corporation (Japan)
The global market for balloon catheters in peripheral arterial disease treatment is experiencing significant growth, primarily driven by the increasing adoption of drug-eluting balloons (DEBs). These devices combine mechanical dilation with localized drug delivery, offering improved outcomes compared to traditional angioplasty. Market analysis indicates that drug-eluting balloons now account for approximately 38% of all peripheral interventions in developed markets, with adoption rates growing at approximately 12% annually in emerging markets. The technology's evolution has enabled more precise drug delivery to affected areas, reducing restenosis rates by up to 60% compared to conventional methods.
Other TrendsMarket Consolidation and Partnership Models
Recent industry movements show a clear trend toward strategic partnerships between medical device manufacturers and pharmaceutical companies specializing in anti-restenosis drugs. This collaboration model has accelerated in the past two years, with 8 major partnerships announced in 2023 alone. These partnerships enable manufacturers to leverage existing drug delivery technologies while pharmaceutical companies gain new application avenues for their therapeutic agents. The collaboration model has proven particularly effective in accelerating regulatory approvals, with joint applications receiving approval 30% faster than solo manufacturer submissions.
The shift toward outpatient settings for peripheral artery interventions continues to accelerate, with 67% of all balloon-based procedures now performed in ambulatory surgical centers or outpatient hospital departments. This transition is driving demand for specialized balloon catheters designed for same-day procedures, with manufacturers developing new product lines specifically for outpatient use. Market analysis indicates outpatient procedures will grow by 18% annually through 2026, creating both opportunities and challenges for manufacturers in terms of device design and distribution strategies.
Regional Analysis: Balloon for Peripheral Arterial Disease MarketEurope
Europe maintains a sophisticated market for peripheral arterial disease devices, with Germany, France, and the UK representing the largest markets. Eastern Europe shows faster growth rates from a lower base, with Poland and Czech Republic expanding capacity. The EU medical device regulatory framework continues to evolve with MDR implementation, creating both challenges and opportunities for balloon catheter manufacturers. European interventional radiologists and vascular surgeons are considered among the world's most skilled, driving adoption of advanced techniques including drug-eluting balloons and combination therapies.
Asia-Pacific
Asia-Pacific demonstrates explosive growth in endovascular procedures, particularly in India where diabetes prevalence drives high demand for peripheral interventions. China's healthcare reform has increased access to interventional radiology in major cities, though rural areas remain underserved. South Korea and Japan maintain world-leading technical success rates for balloon angioplasty, while Australia and New Zealand show high adoption rates per capita. The region hosts growing manufacturing of catheters and balloons, reducing costs through local production.
Latin America
Latin America shows promising growth particularly in Brazil, Mexico, and Argentina where economic development allows increased healthcare spending on peripheral arterial disease. Chile and Colombia demonstrate the fastest growth rates from smaller bases. The region benefits from proximity to North American manufacturers and distributors, facilitating technology transfer and training. Economic challenges in some countries create a preference for value-based purchasing and local manufacturing partnerships over premium-priced imported devices.
Middle East & Africa
The Middle East shows significant variation with Gulf states demonstrating high adoption rates of advanced technologies due to petroleum wealth and international-standard medical centers, while North Africa shows moderate growth led by Egypt and Morocco. Sub-Saharan Africa remains the most underserved region with South Africa accounting for the majority of peripheral interventions, though other countries show rapid growth from minimal bases. The region presents the largest potential market due to demographic trends and disease prevalence, though economic factors constrain current market size.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Medical device manufacturers
Healthcare providers and hospital systems
Biotechnology companies
Investors and venture capitalists
Regulatory bodies and policymakers
-> Global balloon for peripheral arterial disease market was valued at USD 2.02 billion in 2024 and is projected to reach USD 4.25 billion by 2031.
-> Key players include BD, Boston Scientific, Abbott Laboratories, Medtronic, Cook Medical, and Biotronik, among others.
-> The market is expected to grow at a CAGR of 11.5% during the forecast period.
-> North America currently holds the largest market share, while Asia-Pacific is expected to grow at the highest rate.
-> Major segments include ordinary balloons, drug-eluting balloons, and special balloons.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates